AGIOS PHARMACEUTICALS, INC. Lessor, Operating Lease, Payment to be Received, Year Two
AGIOS PHARMACEUTICALS, INC. (AGIO) had Lessor, Operating Lease, Payment to be Received, Year Two of $178.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases › Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity
us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears · last filed 2026-07-30
- 2026-06-30: Lessor, Operating Lease, Payment to be Received, Year Two $178.00K.
- 2026-03-31: Lessor, Operating Lease, Payment to be Received, Year Two $67.00K.
- 2025-12-31: Lessor, Operating Lease, Payment to be Received, Year Two $394.00K.
- 2025-09-30: Lessor, Operating Lease, Payment to be Received, Year Two $394.00K.
| Period end | Lessor, Operating Lease, Payment to be Received, Year Two |
|---|---|
| 2026-06-30 | $178.00K 10-Q · filed 2026-07-30 |
| 2026-03-31 | $67.00K 10-Q · filed 2026-04-29 |
| 2025-12-31 | $394.00K 10-K · filed 2026-02-12 |
| 2025-09-30 | $394.00K 10-Q · filed 2025-10-30 |
| 2023-12-31 | $1.31M 10-K · filed 2024-02-15 |
| 2023-09-30 | $1.31M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.31M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.10M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.46M 10-K · filed 2023-02-23 |
| 2022-09-30 | $4.46M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $4.46M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.19M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.15M 10-K · filed 2022-02-24 |
| 2021-09-30 | $1.15M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |